Please assess the completion status of the following clinical trial:

Trial Title: Pain Reduction With Intranasal Medications for Extremity Injuries

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 8 years to 17 years (up to the 18th birthday)~* Presenting to emergency department with one or more extremity injuries~* Visual analog scale score 35 mm or greater~* Parent or legal guardian present and willing to provide written consent~Exclusion Criteria:~* Received narcotic pain medication prior to arrival~* Evidence of significant head, chest, abdomen, or spine injury~* Glasgow coma score less than 15 or unable to self report pain score~* Nasal trauma or aberrant nasal/airway anatomy~* Active epistaxis~* Allergy to ketamine, fentanyl or meperidine~* Non-English speaking parent and/or child~* History of psychosis~* Postmenarchal female without a urine or serum assay documenting the absence of pregnancy~* Brought in my juvenile detention center or in police custody~* Pregnancy

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Ketamine (Type: EXPERIMENTAL): Ketamine 1.5 mg/kg intranasally for one dose
- Fentanyl (Type: ACTIVE_COMPARATOR): Fentanyl 2 mcg/kg intranasally for one dose

Based on this trial design, predict the completion outcome and termination type (if applicable).